Jeffrey Dunn Sells 3,575 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 3,575 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $15.25, for a total transaction of $54,518.75. Following the sale, the director owned 16,057 shares in the company, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Performance

SiBone stock opened at $15.53 on Wednesday. The firm’s fifty day moving average price is $13.78 and its 200-day moving average price is $15.89. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.99. The stock has a market cap of $688.76 million, a P/E ratio of -39.82 and a beta of 0.70. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The company had revenue of $52.59 million for the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. On average, equities research analysts expect that SiBone will post -0.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SIBN. Wall Street Zen lowered SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Truist Financial reiterated a “buy” rating and issued a $18.00 target price (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Finally, TD Cowen decreased their target price on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Hedge Funds Weigh In On SiBone

Large investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd purchased a new position in SiBone in the 4th quarter worth $29,000. Royal Bank of Canada grew its holdings in SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after acquiring an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after acquiring an additional 1,941 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in SiBone in the 4th quarter worth $53,000. Finally, State of Wyoming bought a new stake in SiBone in the 2nd quarter worth $55,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.